Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0P9FT
|
|||
| Former ID |
DIB011542
|
|||
| Drug Name |
REC-15-2739
|
|||
| Synonyms |
Upidosin; UPIDOSIN; Rec-15-2739; 152735-23-4; UNII-TXG28R7G4Y; TXG28R7G4Y; CHEMBL278865; 4H-1-Benzopyran-8-carboxamide,N-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]-3-methyl-4-oxo-2-phenyl-; Upidosin [INN]; N-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-3-methyl-4-oxo-2-phenylchromene-8-carboxamide; SB 216469-S; Rec 15-2739; ACMC-20n6iu; AC1L3XX2; GTPL496; SCHEMBL6638869; CTK4C7558; DTXSID70165115; Rec 15/2739; ZINC3796141; BDBM50057465; AKOS030553705; SB 216469; L000508; SB-216469; REC-15-2869; REC-15-3011; REC-22/009
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Prostate disease [ICD-11: GA91; ICD-10: N42.9] | Discontinued in Phase 2 | [1] | |
| Company |
Recordati SpA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C31H33N3O4
|
|||
| Canonical SMILES |
CC1=C(OC2=C(C1=O)C=CC=C2C(=O)NCCCN3CCN(CC3)C4=CC=CC=C4OC)C5=CC=CC=C5
|
|||
| InChI |
1S/C31H33N3O4/c1-22-28(35)24-12-8-13-25(30(24)38-29(22)23-10-4-3-5-11-23)31(36)32-16-9-17-33-18-20-34(21-19-33)26-14-6-7-15-27(26)37-2/h3-8,10-15H,9,16-21H2,1-2H3,(H,32,36)
|
|||
| InChIKey |
DUCNHKDCVVSJLG-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 152735-23-4
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor alpha-1A (ADRA1A) | Target Info | Inhibitor | [2] |
| Adrenergic receptor alpha-1D (ADRA1D) | Target Info | Modulator | [3] | |
| KEGG Pathway | Calcium signaling pathway | |||
| cGMP-PKG signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Adrenergic signaling in cardiomyocytes | ||||
| Vascular smooth muscle contraction | ||||
| Salivary secretion | ||||
| AMPK signaling pathway | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Panther Pathway | Alpha adrenergic receptor signaling pathway | |||
| Reactome | Adrenoceptors | |||
| G alpha (q) signalling events | ||||
| G alpha (12/13) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| Calcium Regulation in the Cardiac Cell | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| Endothelin Pathways | ||||
| AMPK Signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003537) | |||
| REF 2 | Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64. | |||
| REF 3 | Functional antagonistic activity of Rec 15/2739, a novel alpha-1 antagonist selective for the lower urinary tract, on noradrenaline-induced contraction of human prostate and mesenteric artery. J Pharmacol Exp Ther. 1996 Jun;277(3):1237-46. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.